"Designing Growth Strategies is in our DNA"

North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Histone Deacetylase (HDAC) Inhibitors, Monoclonal Antibody, Antineoplastic Agent, and Others), By Disease Type (Mycosis Fungoides (MF), Sezary Syndrome (SS), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecasts, 2021-2028

Last Updated: February 10, 2025 | Format: PDF | Report ID: FBI106325

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Key Industry Developments
    2. Regulatory & Reimbursement Overview - U.S.
    3. Impact of COVID-19 on the Market
    4. Overview: Advancements in Cutaneous T-Cell Lymphoma (CTCL) Therapeutics
    5. Future Treatment Trends in Cutaneous T-Cell Lymphoma (CTCL) Therapeutics
    6. Overview: Aging Population, U.S., 2020
  5. Epidemiology
    1. Prevalence of Cutaneous T-Cell Lymphoma (CTCL) - U.S.
    2. Incidence of Cutaneous T-Cell Lymphoma (CTCL) - U.S.
  6. Pipeline Analysis
    1. Pipeline Assessment
    2. Profiles of Key Drug Candidates in Late Stages of Development
  7. North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Antineoplastic Agent
      2. Histone Deacetylase (HDAC) Inhibitors
      3. Monoclonal Antibodies
      4. Others (Psoralens, etc.)
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Mycosis Fungoides (MF)
      2. Sezary Syndrome (SS)
      3. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospitals Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  8. Competitive Analysis
    1. North America Market Share Analysis (2020)
    2. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Kyowa Kirin, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Ortho Dermatologics
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Merck & Co., Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Stiefel Laboratories, Inc. (GlaxoSmithKline plc)
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Helsinn Healthcare SA
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. Pfizer Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. Mallinckrodt Pharmaceuticals
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
  9. Strategic Recommendations
Read Less

Figure 1:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue Breakdown (USD million, %), by Country, 2020 & 2028

Figure 2:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Value (USD million), by Drug Class, 2020 & 2028

Figure 3:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue Share (%), by Drug Class, 2020

Figure 4:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Value (USD million), by Disease Type, 2020 & 2028

Figure 5:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue Share (%), by Disease Type, 2020

Figure 6:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Value (USD million), by Distribution Channel, 2020 & 2028

Figure 7:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue Share (%), by Distribution Channel, 2020

Figure 8:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Value (USD million), by Country, 2020 & 2028

Figure 9:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue Share (%), by Country, 2020

Figure 10:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Share Analysis (%), By Company, 2020

Table 1:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue (USD million) Forecast, By Drug Class, 2017-2028

Table 2:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue (USD million) Forecast, by Disease Type, 2017-2028

Table 3:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue (USD million) Forecast, by Distribution Channel, 2017-2028

Table 4:  North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Revenue (USD million) Forecast, by Country, 2017-2028

North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Size, Share and Global Industry Trend Forecast till 2028
  • 2017-2028
  • 2020
  • 2017-2019
  • 73
Consulting Services
    How will you benefit from our consulting services ?